Dare Bioscience Files 8-K: Reg FD & Financials

Ticker: DARE · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1401914

Sentiment: neutral

Topics: disclosure, financials, regulatory

TL;DR

Dare Bioscience filed an 8-K on Feb 10, 2025, covering Reg FD and financials. Standard update.

AI Summary

On February 10, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides updates on regulatory disclosures and financial statements, which are crucial for investors to understand the company's current standing and compliance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and regulatory information, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What specific items are covered in this 8-K filing by Dare Bioscience, Inc.?

This 8-K filing covers Regulation FD Disclosure and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 10, 2025.

What is the principal executive office address for Dare Bioscience, Inc.?

The principal executive office address is 3655 Nobel Drive, Suite 260, San Diego, CA 92122.

What were some of Dare Bioscience, Inc.'s former company names?

Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.

In which state is Dare Bioscience, Inc. incorporated?

Dare Bioscience, Inc. is incorporated in Delaware.

Filing Stats: 619 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-02-10 08:01:08

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: February 10, 2025 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing